Know Cancer

forgot password

A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors

Phase 1
18 Years
Not Enrolling
Advanced Solid Tumours, Cancer, Lung Cancer, Non-Small Cell

Thank you

Trial Information

A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors

Inclusion Criteria:

A subject will be considered eligible for inclusion in this study only if all of the
following criteria are met:

- Subjects must provide written informed consent prior to performance of study specific
procedures or assessments, and must be willing to comply with treatment and follow

·Procedures conducted as a part of routine clinical management of the subject (e.g.,
blood count, imaging study) and obtained prior to signed informed consent may be
utilized for Screening or Baseline purposes provided these tests are obtained as
specified in the protocol.

- Histologically- or cytologically-confirmed diagnosis of advanced solid tumor that has
failed standard therapy or for which there is no standard therapy. Subjects for whom
erlotinib or pemetrexed are standard therapy may also be entered.

- Age ≥18 years.

- ECOG Performance status must be ≤1.

- Adequate organ system function as defined in Table 9. System (Laboratory Values)


Absolute neutrophil count (ANC) ((≥1.5 X 10^9/L)) Hemoglobin (≥10 g/dL) Platelets (≥ 100 X
10^9/L) Prothrombin time (PT) or international normalized ration (INR) (≤ 1.2 X upper
limit of normal (ULN)) Activated partial thromboplastin time (APTT) (≤ 1.2 X ULN)


Total bilirubin (≤1.5 X ULN) AST and ALT (≤ 2.5 X ULN)


Serum creatinine (≤ 1.5 mg/dL) Or, if greater than 1.5 mg/dL Calculated creatinine
clearance (≤ 50 mL/min) Urine Protein to Creatinine Ratio (UPC)2 < 1

1. Subjects may not have had a transfusion within 7 days of screening assessment.

2. If UPC ≥ 1, then a 24-hour urine protein must be assessed and 24-hour urine protein
must be <1 g protein to be eligible.

- Measurable disease on CT scan.

- A female subject is eligible to enter and participate in the study if she is of:
• Non-childbearing potential (i.e., physiologically incapable of becoming
pregnant), including any woman who has had:• A hysterectomy

- A bilateral oophorectomy (ovariectomy)

- A bilateral tubal ligation

- Is post-menopausal:

- Subjects not using hormone replacement therapy (HRT) must have experienced total
cessation of menses for ≥1 year and be greater than 45 years in age, OR, in
questionable cases, have a follicle stimulating hormone (FSH) value >40mIU/mL
and an estradiol value <40pg/mL (<140pmol/L).

- Subjects must discontinue HRT prior to study enrollment due to the potential for
inhibition of CYP enzymes that metabolize estrogens and progestins (see Section
8). For most forms of HRT, at least 2 4 weeks must elapse between the cessation
of HRT and determination of menopausal status; length of this interval depends
on the type and dosage of HRT. If a female subject is determined not to be
post-menopausal, they must use adequate contraception, as defined immediately

- OR of Childbearing potential, including any female who has had a negative serum
pregnancy test within 2 weeks prior to the first dose of study treatment,
preferably as close to the first dose as possible, and agrees to use adequate
contraception. GSK acceptable contraceptive methods, when used consistently and
in accordance with both the product label and the instructions of the physician,
are as follow:

- An intrauterine device with a documented failure rate of less than 1% per year.

- Vasectomized partner who is sterile prior to the female subject's entry and is
the sole sexual partner for that female.

- Complete abstinence from sexual intercourse for 14 days before exposure to
investigational product, through the dosing period, and for at least 21 days
after the last dose of investigational product.

- Double-barrier contraception (condom with spermicidal jelly, foam suppository,
or film; diaphragm with spermicide; or male condom and diaphragm with

Note: Oral contraceptives are not reliable due to potential drug-drug interactions.

Female subjects who are lactating should discontinue nursing prior to the first dose of
study drug and should refrain from nursing throughout the treatment period and for 14 days
following the last dose of study drug.

A male with a female partner of childbearing potential is eligible to enter and
participate in the study if he uses a barrier method of contraception or abstinence during
the study.

- For Arm B (pemetrexed plus pazopanib) subjects:

- Must be able to permanently discontinue aspirin dose of ≥1.3 g/day for ≥10 days
before through ≥10 days after pemetrexed disodium treatment. All subjects should be
able to interrupt intake of NSAIDs with longer half lives (e.g., nabumetone,
piroxicam, oxaprozin) for at least 5 days before, the day of, and 2 days following
pemetrexed disodium administration.

- With mild to moderate renal insufficiency (CrCl from 50-79mL/min) should avoid taking
NSAIDs with short elimination half lives (e.g., fenoprofen, indomethacin, ketoprofen,
tolmetin, meclofenamate) for a period of 2 days before, the day of, and 2 days
following administration of pemetrexed disodium.

Exclusion Criteria:

- Prior use of pazopanib, erlotinib (for subjects in Arm A), or pemetrexed (for
subjects in Arm B).

- History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
metastases, are asymptomatic, and have had no requirement for steroids or
anti‑seizure medication for one week prior to date of first dose of study drug.
Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance
imaging [MRI]) is required for all subjects.

- Clinically significant gastrointestinal abnormalities which might interfere with oral
dosing, including but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel that could affect the absorption of
study drug

- Active peptic ulcer disease

- Inflammatory bowel disease

- Ulcerative colitis, or other gastrointestinal conditions with increased risk of

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 28 days prior to beginning study treatment.

- Presence of uncontrolled infection

- Prolongation of corrected QT interval (QTc) > 480 msecs.

- History of any one of more of the following cardiovascular conditions within the past
6 months:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- Symptomatic peripheral vascular disease

- Class III or IV congestive heart failure as defined by the New York Heart Association

- Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140mmHg
or diastolic blood pressure (DBP) of ≥ 90mmHg]. Note: Initiation or adjustment of
antihypertensive medication(s) is permitted prior to study entry. Blood pressure
must be re-assessed on two occasions that are separated by a minimum of 24 hours. The
mean SBP / DBP values from each blood pressure assessment must be < 140/90mmHg in
order for a subject to be eligible for the study.

- History of cerebrovascular accident (CVA), pulmonary embolism or insufficiently
treated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with
recent DVT who have been treated with therapeutic anti coagulant agents (excluding
therapeutic warfarin) for at least 6 weeks are eligible. As noted in Section 8.2, use
of therapeutic levels of warfarin must have ended more than 14 days prior to first
dose of study drug.

- Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer.

- Evidence of active bleeding or bleeding diathesis.

- Hemoptysis within 6 weeks prior to first dose of study drug.

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance to study procedures.

- Is unable or unwilling to discontinue prohibited medications, as listed in Section
8.2, for 14 days or five half-lives (whichever is longer) of a drug prior to the
first dose of study drug and for the duration of the study.

- Use of an investigational agent, including an investigational anti-cancer agent,
within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study

- Prior use of an investigational or licensed tyrosine kinase inhibitor that targets
VEGF receptors. Note: Prior use of bevacizumab is allowed.

- Is now undergoing and/or has undergone in the 28 days immediately prior to first dose
of study drug, any cancer therapy (surgery, tumor embolization, chemotherapy,
radiation therapy, immunotherapy, biological therapy, or hormonal therapy). Note:
For prior bevacizumab therapy, at least 40 days should have elapsed between last dose
of bevacizumab and first dose of study drug.

- Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 (with the
exception of Grade 2 alopecia) and/or that is progressing in severity.

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib, erlotinib, or pemetrexed.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD regimen for each combination regimen in each arm of the study as determined by an evaluation of AEs and changes in laboratory values. The MTD = highest dosing regimen that results in dose limiting toxicity in <= 1 of 6 patients.

Outcome Time Frame:

Through a minimum of two cycles of therapy for each subject

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Italy: Isituto Superiore di Sanita'

Study ID:




Start Date:

November 2007

Completion Date:

September 2009

Related Keywords:

  • Advanced Solid Tumours
  • Cancer
  • Lung Cancer, Non-Small Cell
  • erlotinib
  • pharmacokinetics
  • Solid tumors
  • pemetrexed
  • anti-angiogenesis
  • pazopanib (GW786034)
  • cytokine and angiogenic factors
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Neoplasms



GSK Investigational SiteGermantown, Tennessee  38138
GSK Investigational SiteNew York, New York  10021
GSK Investigational SiteAurora, Colorado  80012